Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation (LENEA)
This study is currently recruiting participants.
Verified November 2012 by Sorin Group
Sponsor:
Sorin Group
Information provided by (Responsible Party):
Sorin Group
ClinicalTrials.gov Identifier:
NCT01731210
First received: November 15, 2012
Last updated: November 20, 2012
Last verified: November 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The LENEA study is an international, prospective, open label, non-randomized multicenter clinical research study designed to assess the safety and effectiveness of the NANO LV lead system.
| Condition | Intervention | Phase |
|---|---|---|
|
LV Lead LV Therapy LV Treatment LV Microcable |
Device: implantation of the new LV lead: NANO system. |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation |
Further study details as provided by Sorin Group:
Primary Outcome Measures:
- Freedom from left ventricular lead related complications through 1 month [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 128 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | November 2014 |
| Estimated Primary Completion Date: | November 2013 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Approved indication per ACC/AHA/HRS guidelines for implantation of a CRT-D system for treatment of heart failure or life threatening ventricular tachyarrhythmia(s)
- Receiving a new implant OR undergoing an upgrade from an existing ICD or pacemaker implant with no prior implanted LV lead OR undergoing a new LV implant attempt consecutive to a recent LV lead placement failure not related to coronary sinus cannulation failure
- Patient receiving the PARADYM RF CRT or PARADYM RF CRT SONR devices
- Ability to provide informed consent for study participation and is willing and able to comply with the prescribed follow-up tests and schedule of evaluations
Exclusion Criteria:
- Ventricular tachyarrhythmia of transient or reversible causes such as acute myocardial infarction, digitalis intoxication, drowning, electrocution, electrolyte imbalance, hypoxia or sepsis, uncorrected at the time of the enrolment;
- Incessant Ventricular tachyarrhythmias;
- Unstable angina, or acute MI , CABG , or PTCA within the past 4 weeks;
- Correctable valvular disease that is the primary cause of heart failure;
- Post heart transplant (patients who are waiting for a heart transplant are allowed in the study);
- Patient who had previously a permanently implanted LV lead;
- Concurrent implant with another pacemaker or ICD (previously implanted pacemaker or ICD devices should be removed prior to implant with the Paradym RF CRT-D or Paradym RF CRT SONR);
- Already included in another clinical study that could confound the results of this study;
- Life expectancy less than 1 year.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01731210
Contacts
| Contact: Frédéric Mr ANSELME, MD | + 33 (0)2 32 88 86 25 | frederic.anselme@chu-rouen.fr |
| Contact: Ghislaine Mrs GESTIN | +33 1 46 01 36 06 | ghislaine.gestin@sorin.com |
Locations
| France | |
| CHU Charles Nicolle | Recruiting |
| Rouen, France, 76000 | |
Sponsors and Collaborators
Sorin Group
More Information
No publications provided
| Responsible Party: | Sorin Group |
| ClinicalTrials.gov Identifier: | NCT01731210 History of Changes |
| Other Study ID Numbers: | LCNA02 - LENEA |
| Study First Received: | November 15, 2012 |
| Last Updated: | November 20, 2012 |
| Health Authority: | France: National agency of health and medecine Germany: Federal Institute for Drugs and Medical Devices United Kingdom: Medicines and Healthcare Products Regulatory Agency Spain: ministery of health Italy: ministery of health |
ClinicalTrials.gov processed this record on May 23, 2013